Source-grounded facts extracted from Aligos Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aligos Therapeutics, Inc. reported first quarter 2026 results: net income Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $, EPS $(2.21).
“Net loss for the three months ended March 31, 2026 was $23.0 million or basic and diluted net loss per common share of $(2.21)”
Aligos Therapeutics, Inc. entered into License Agreement with Xiamen Amoytop Biotech Co., Ltd. valued at $25 million (effective 2026-04-16).
“On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest”
Aligos Therapeutics, Inc. reported the fourth quarter and full year 2025 results: net income Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share o, EPS $(1.91).
“Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share of $(1.91), compared to net loss of $82.2 million or basic and diluted net loss per common share of $(13.08) for the three months ended December 31, 2024.”
Aligos Therapeutics, Inc.: Increased authorized shares of voting common stock from 20,000,000 to 100,000,000 and non-voting common stock from 800,000 to 15,800,000 (effective 2025-06-25).
“The increase in the number of authorized shares voting common stock and non-voting common stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 25, 2025 and was effective as of such date.”
Lesley Ann Calhoun was appointed as Chief Operating Officer at Aligos Therapeutics, Inc..
“On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.”
Margarita Chavez was appointed as Director at Aligos Therapeutics, Inc..
“appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships”
Heather Preston was appointed as Director at Aligos Therapeutics, Inc..
“appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships”
Jack Nielsen resigned as Director at Aligos Therapeutics, Inc..
“The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after Mr. Nielsen’s resignation.”
Matthew McClure resigned as Chief Medical Officer at Aligos Therapeutics, Inc..
“On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.”
Aligos Therapeutics, Inc. reported first quarter 2024 results: net income Net losses for the three months ended March 31, 2024 were $34.9 million, EPS basic and diluted net loss per common share of $(0.22).
“Net losses for the three months ended March 31, 2024 were $34.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $23.0 million or basic and diluted net loss per common share of $(0.53) for the three months ended March 31, 2023.”
Aligos Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $87.7 million, EPS $(1.36).
“Net losses for the year ended December 31, 2023 were $87.7 million or basic and diluted net loss per common share of $(1.36), compared to net losses of $96.0 million or basic and diluted net loss per common share of $(2.25) for the year ended December 31, 2022.”
Aligos Therapeutics, Inc. reported the three months ended December 31, 2023 results: net income $27.9 million, EPS $(0.22).
“Net losses for the three months ended December 31, 2023 were $27.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $21.9 million or basic and diluted net loss per common share of $(0.51) for the three months ended December 31, 2022.”
Leonid Beigelman resigned as President at Aligos Therapeutics, Inc..
“On November 20, 2023, in connection with the previously disclosed resignation of Leonid Beigelman, President of Aligos Therapeutics, Inc. (the “Company”), the Company and Dr. Beigelman entered into a separation and release agreement”
Leonid Beigelman resigned as President at Aligos Therapeutics, Inc..
“On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.”
Leonid Beigelman resigned as Member of the Board of Directors at Aligos Therapeutics, Inc..
“On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.”
Aligos Therapeutics, Inc. reported the third quarter 2023 results: net income $18.0 million, EPS $(0.41).
“Net losses for the three months ended September 30, 2023 were $18.0 million or basic and diluted net loss per common share of $(0.41)”
Aligos Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at approximately $92,149,996 (effective 2023-10-23).
“On October 23, 2023, Aligos Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).”
Aligos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“rough September 1, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until March 4, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.”
Aligos Therapeutics, Inc. reported three months ended June 30, 2023 results: net income $18.8 million, EPS $(0.43).
“Net losses for the three months ended June 30, 2023, were $18.8 million or basic and diluted net loss per common share of $(0.43), compared to net losses of $19.9 million or basic and diluted net loss per common share of $(0.47) for the three months ended June 30, 2022.”
Aligos Therapeutics, Inc. shareholders approved Ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-07-20 meeting.
“Proposal 2 . The ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 34,670,204 11,096 918”
Aligos Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. at the 2023-07-20 meeting.
“Proposal 1 . The election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jack B. Nielsen 20,201,692 4,766,666 9,713,860 Bridget Martell, M.A., M.D. 24,022,757 945,601 9,713,860 Carole Nuechterlein, J.D. 21,653,372 3,314,986 9,713,860”
Aligos Therapeutics, Inc. reported first quarter 2023 results: net income $23.0 million, EPS $(0.53).
“Net losses for the three months ended March 31, 2023, were $23.0 million or basic and diluted net loss per common share of $(0.53), compared to net losses of $35.6 million or basic and diluted net loss per common share of $(0.84) for the three months ended March 31, 2022.”
Aligos Therapeutics, Inc. reported the fourth quarter and full year 2022 results: net income Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha, EPS $(0.51).
“Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common share of $(0.51), compared to net losses of $37.7 million or basic and diluted net loss per common share of $(0.89) for the three months ended December 31, 2021. Net losses for the year ended December 31, 2022, were $96.0 million or basic and diluted net loss per common share of $(2.25), compared to net losses of $128.3 million or basic and diluted net loss per common share of $(3.22) for the year ended December 31, 2021.”
Aligos Therapeutics, Inc. reported third quarter, September 30, 2022 results: net income Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh, EPS $(0.44).
“Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common share of $(0.44), compared to net losses of $33.1 million or basic and diluted net loss per common share of $(0.78) for the three months ended September 30, 2021.”
Bridget Martell was appointed as Class III director at Aligos Therapeutics, Inc..
“appointed Bridget Martell, M.D., to the Board to fill the newly created directorship resulting from the increase in the number of authorized directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.